Form 4: Cellectar Director Sells 198 Shares in Pre-Planned Trade
Insider Transaction Report
Cellectar Biosciences Director John Neis reported a pre-planned sale of 198 common shares at a weighted average price of $3.6969, effective December 12, 2025.
Summary
- John Neis, a Director of Cellectar Biosciences, Inc. (CLRB), reported a sale of 198 shares of common stock.
- The transaction occurred on December 12, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.
- The shares were sold at a weighted average price of $3.6969, with individual transactions ranging from $3.631 to $3.70.
- Following this transaction, Neis directly beneficially owns 10 shares.
- The reported share numbers have been adjusted for three reverse stock splits: 1:30 on June 24, 2025; 1:10 on July 21, 2022; and 1:10 on July 16, 2018.
- Neis also has indirect beneficial ownership through Advantage Capital Wisconsin Partners I, Limited Partnership, where he is one of five managers of the submanager, Venture Investors LLC, disclaiming ownership except for his pecuniary interest.
Sentiment
Score: 5
Explanation: A director's sale, even small and pre-planned, is generally neutral to slightly negative, but the small volume and 10b5-1 plan mitigate significant negative sentiment.
Negatives
- A director selling shares, even a small amount, can sometimes be perceived negatively by the market, though this transaction is pre-planned under Rule 10b5-1.
Industry Context
This filing reports a routine insider transaction, which is common across all industries for directors and officers managing their personal equity holdings, often through pre-arranged trading plans.
Stakeholder Impact
- Shareholders: A director's sale, even small, might be interpreted by some shareholders as a lack of confidence, though the 10b5-1 plan suggests it's for personal financial planning rather than market timing. The impact is likely minimal due to the small number of shares.
Key Dates
| Date | Description |
|---|---|
| 07/16/2018 | Effective date of a one-for-ten (1:10) reverse stock split by the Issuer. |
| 07/21/2022 | Effective date of a one-for-ten (1:10) reverse stock split by the Issuer. |
| 06/24/2025 | Effective date of a one-for-thirty (1:30) reverse stock split by the Issuer. |
| 12/12/2025 | Date of the reported transaction (sale of common stock by John Neis). |
| 12/16/2025 | Date the Form 4 was signed and filed. |
Recommendation
holdThe filing reports a small, pre-planned sale of 198 shares by a director under a Rule 10b5-1 plan. This type of transaction is typically for personal liquidity management and does not usually signal a change in the company's fundamental outlook. Given the minimal volume and the pre-scheduled nature, it provides no new information to warrant a change in investment stance, hence a 'hold' recommendation.
Keywords
Cellectar Biosciences, CLRB, John Neis, Insider Sale, Form 4, Director Transaction, Stock Split, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.